Faculty Advisor
Manning, Amity L.
Abstract
Acute Myeloid Leukemia (AML) is the most common type of blood cancer to occur in adults. AML patients are commonly treated with chemotherapeutic approaches. However, these approaches target pathways common in all proliferating cells, resulting in damaged healthy tissues. Currently, the identification and development of therapies that specifically or preferentially impact growth of leukemia cells is in high demand. Alisertib, an inhibitor of Aurora A kinase, is being investigated clinically as a co-therapeutic for AML. Our studies have focused on exploring the molecular effects of Aurora A inhibition, and investigating cellular biomarkers that may predict drug sensitivity in AML patients. Our results suggest that an increased centriole number confers resistance of AML cells to Alisertib.
Publisher
Worcester Polytechnic Institute
Date Accepted
March 2017
Major
Biology and Biotechnology
Project Type
Major Qualifying Project
Copyright Statement
All authors have granted to WPI a nonexclusive royalty-free license to distribute copies of the work, subject to other agreements. Copyright is held by the author or authors, with all rights reserved, unless otherwise noted.
Accessibility
Unrestricted
Advisor Department
Biology and Biotechnology